Market Cap 8.61M
Revenue (ttm) 890,000.00
Net Income (ttm) -21.65M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,432.58%
Debt to Equity Ratio 0.19
Volume 124,000
Avg Vol 254,130
Day's Range N/A - N/A
Shares Out 5.41M
Stochastic %K 71%
Beta 0.25
Analysts Strong Sell
Price Target $14.00

Company Profile

Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fishe...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 49 6131 554 2860
Address:
Robert Koch Strasse 50, Mainz, Germany
Duskfall
Duskfall Oct. 23 at 5:10 PM
$MYNZ 👍
0 · Reply
Manwiththeplan
Manwiththeplan Oct. 21 at 3:13 PM
$MYNZ how will this company solve its financial situation?
3 · Reply
BlueSquirrel7
BlueSquirrel7 Oct. 21 at 10:43 AM
$MYNZ What do you think about competition with Galleri tests for detecting about 50 types of cancer from Grail?
0 · Reply
BlueSquirrel7
BlueSquirrel7 Oct. 20 at 5:58 AM
$MYNZ What would be the next catalysts for MYNZ? Thank you!
1 · Reply
twixbarrtwits
twixbarrtwits Oct. 18 at 5:29 PM
1 · Reply
andreatorchio1970
andreatorchio1970 Oct. 17 at 7:23 PM
$MYNZ gooooo
0 · Reply
Genesys01
Genesys01 Oct. 16 at 9:28 PM
$MYNZ A very interesting German company which nobody has on the radar until now. Could be a mistake, because this is NOT an Israeli Scam.
2 · Reply
Tbio64
Tbio64 Oct. 15 at 1:26 PM
$MYNZ news out...
1 · Reply
Tbio64
Tbio64 Oct. 15 at 1:26 PM
$MYNZ news
0 · Reply
Duncan_
Duncan_ Oct. 14 at 7:26 PM
$MYNZ Pancreatic cancer is a malignant neoplasm of the pancreas with one of the highest mortality rates of all major cancers. Each year, about 466,000 lives are taken globally, and it’s the seventh leading cause of cancer-related death worldwide.1 It has one of the lowest survival rates of any cancer, with typically late detection and poor outcomes with standard of care treatment(s). The 5-year overall survival rate is approximately 11% in the U.S.2 and 9% globally.3 However, if diagnosis occurs in the early stages of the disease, the survival rate is significantly higher.
0 · Reply
Latest News on MYNZ
Mainz Biomed Expands into Switzerland with labor team w

Feb 20, 2025, 8:01 AM EST - 8 months ago

Mainz Biomed Expands into Switzerland with labor team w


Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

Dec 16, 2024, 5:00 PM EST - 11 months ago

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering


Mainz Biomed Announces Stock Split

Nov 29, 2024, 8:45 AM EST - 11 months ago

Mainz Biomed Announces Stock Split


Mainz Biomed Provides Half Year 2024 Corporate Update

Jul 2, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Provides Half Year 2024 Corporate Update


Mainz Biomed Reports Results of 2024 Annual General Meeting

May 31, 2024, 5:01 PM EDT - 1 year ago

Mainz Biomed Reports Results of 2024 Annual General Meeting


Mainz Biomed Reports Full Year 2023 Financial Results

Apr 9, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Reports Full Year 2023 Financial Results


Mainz Biomed Provides Year-End Corporate Review 2023

Jan 9, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Provides Year-End Corporate Review 2023


Duskfall
Duskfall Oct. 23 at 5:10 PM
$MYNZ 👍
0 · Reply
Manwiththeplan
Manwiththeplan Oct. 21 at 3:13 PM
$MYNZ how will this company solve its financial situation?
3 · Reply
BlueSquirrel7
BlueSquirrel7 Oct. 21 at 10:43 AM
$MYNZ What do you think about competition with Galleri tests for detecting about 50 types of cancer from Grail?
0 · Reply
BlueSquirrel7
BlueSquirrel7 Oct. 20 at 5:58 AM
$MYNZ What would be the next catalysts for MYNZ? Thank you!
1 · Reply
twixbarrtwits
twixbarrtwits Oct. 18 at 5:29 PM
1 · Reply
andreatorchio1970
andreatorchio1970 Oct. 17 at 7:23 PM
$MYNZ gooooo
0 · Reply
Genesys01
Genesys01 Oct. 16 at 9:28 PM
$MYNZ A very interesting German company which nobody has on the radar until now. Could be a mistake, because this is NOT an Israeli Scam.
2 · Reply
Tbio64
Tbio64 Oct. 15 at 1:26 PM
$MYNZ news out...
1 · Reply
Tbio64
Tbio64 Oct. 15 at 1:26 PM
$MYNZ news
0 · Reply
Duncan_
Duncan_ Oct. 14 at 7:26 PM
$MYNZ Pancreatic cancer is a malignant neoplasm of the pancreas with one of the highest mortality rates of all major cancers. Each year, about 466,000 lives are taken globally, and it’s the seventh leading cause of cancer-related death worldwide.1 It has one of the lowest survival rates of any cancer, with typically late detection and poor outcomes with standard of care treatment(s). The 5-year overall survival rate is approximately 11% in the U.S.2 and 9% globally.3 However, if diagnosis occurs in the early stages of the disease, the survival rate is significantly higher.
0 · Reply
Duncan_
Duncan_ Oct. 14 at 7:26 PM
$MYNZ “We are excited about the collaboration with Liquid Biosciences on PancAlert, which is being developed for early-stage disease detection. A first-in-class screening test for pancreatic cancer would be a major achievement in the fight of this devastating disease,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Liquid Biosciences is already a key partner for our next generation colorectal cancer screening test. Expanding our partnership will allow us to leverage the power of AI also for the detection of this deadly form of cancer.”
1 · Reply
Duncan_
Duncan_ Oct. 14 at 7:25 PM
$MYNZ cont. The recently completed first phase of the collaboration included the evaluation of biomarkers from the Company’s research program co-funded by the German Federal Ministry for Education and Research, and applied a single algorithm developed by Liquid Biosciences using its EMERGE platform. The results of this feasibility analysis were promising, leading the Company and Liquid Biosciences to believe that a PancAlert diagnostic test could, in the future, be combined with Mainz Biomed’s colorectal cancer screening product. The Company and Liquid Biosciences plan to continue with the second phase of the collaboration, for which the evaluation of biomarkers will be expanded to include the microbiome biomarkers that were analyzed in collaboration with Microba Life Sciences in 2023, as well as an extension of the AI algorithm. The companies plan to complete this analysis in the fourth quarter of 2024.
0 · Reply
Duncan_
Duncan_ Oct. 14 at 7:24 PM
$MYNZ Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert article : link https://finance.yahoo.com/news/mainz-biomed-partners-liquid-biosciences-080100831.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAACKnpS-Lcr-3EF8lJgtNUDY2qr7ZOTjAO3p5lnUgX5gEQcmZTHFzpgDz4UrMo9bjEI6qm4FtGkRkdNie_wYi_z5EMh7Kb2dELFyQxj1nswqpRvwMZB74stshuxMlsF0E3QGKmEuTQmtVi0iOgT-G5LyAb794cYaN20UBhgs2Bgbw PancAlert is a Next-Generation Pancreatic Cancer Detection Test in Mainz Biomed’s Research and Development Pipeline – Promising Results of First Analysis BERKELEY, Calif. and MAINZ, Germany, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the expansion of its collaboration with Liquid Biosciences to Mainz Biomed’s next-generation detection test for pancreatic cancer. The companies will leverage Liquid Biosciences proprietary AI analysis technology platform (EMERGE) to expand and optimize the selection of novel biomarkers for PancAlert.
0 · Reply
Bogdanoff2142
Bogdanoff2142 Oct. 14 at 2:12 PM
$CING decent volume for the first half hour. NDA acceptance and soon patent news, first adhd drug that is active a whole day with a single pill. $MYNZ $SPRB $IXHL $DRUG
1 · Reply
SMARTR8
SMARTR8 Oct. 14 at 2:04 PM
$MYNZ Stop missing out 🤫
0 · Reply
SMARTR8
SMARTR8 Oct. 14 at 1:49 PM
$MYNZ bought starter at 1.50 ✅️🤝
0 · Reply
Xochi_Resaerch_Group
Xochi_Resaerch_Group Oct. 13 at 8:50 PM
$MYNZ obviously back down lol
0 · Reply
ridgecrest123
ridgecrest123 Oct. 12 at 12:14 AM
$MYNZ As a physician this seems like a game changer. Pancreatic cancer is usually detected when a cure is no longer possible. It has one of the highest mortality rates of any cancer. The ColoAlert is an appetizer and certainly valuable but offering a possible early diagnosis of pancreatic cancer with a simple blood test is not only financially rewarding as an investor, but potentially will save thousands if not millions of lives
1 · Reply
Orlandotrader
Orlandotrader Oct. 10 at 6:34 PM
$MYNZ The study used a set of 18 biomarkers owned by Liquid Biosciences to test a patient's blood for pancreatic cancer. The test achieved 100% sensitivity, identifying every person with pancreatic cancer, and 95% specificity, identifying most people without the cancer. Great Results folks. Hand in this Company will Eventually get Recognition. When it does to the Moon Alice. Market cap will climb rapidly and the company will be able to Raise Real Money to Develop Cholo Alert and The Pancreatic Test Kit.
1 · Reply
benzinga
benzinga Oct. 10 at 4:52 PM
Mainz Biomed Update: Early Detection Test For Pancreatic Cancer Demonstrates Never Before Seen Results, Company Ready To Launch ColoAlert In Switzerland $MYNZ https://www.benzinga.com/partner/biotech/25/10/48145433/mainz-biomed-update-early-detection-test-for-pancreatic-cancer-demonstrates-never-before-seen-res
0 · Reply
_CircuitBreaker
_CircuitBreaker Oct. 9 at 11:18 PM
Keep a close watch on CMCT! $MYNZ $UA $AGMH $MNST 1
0 · Reply
ASTS11
ASTS11 Oct. 9 at 4:02 PM
$BURU $MYNZ Mainz Biomed (NASDAQ:MYNZ) reported topline feasibility results for a non-invasive, blood-based pancreatic cancer screening test using 18 licensed biomarkers. In a 30-subject cohort the leading panel achieved 100% sensitivity and 95% specificity, and the algorithm also detected precancerous lesions. These results align with earlier discovery/validation datasets that showed 95% sensitivity and 98% specificity. Mainz Biomed will plan a larger confirmatory study using banked retrospective samples, then a PCR-based validation study and potential future FDA submission, pending outcomes.
0 · Reply